Clinical reviewer: Dr. Sarah Boss, MD

This guide is published by COGNIFUL, part of THE BALANCE GROUP. It compares selected Swiss clinical routes and our potential later residential role. The providers are not interchangeable, and inclusion does not constitute an independent ranking of luxury facilities or a guarantee of admission.

Drug detox can mean very different things in different inquiries. One person may need management of an acute substance-related illness, another a review of prescribed medication, and another continuing treatment for a substance use disorder. Ask the assessing professional to explain the main problem, the immediate risks and the purpose of the proposed admission.

Provide the actual substances, prescriptions, alcohol use, recent changes and previous treatment history. Describe uncertain products accurately rather than assigning them an assumed identity. The assessment should include earlier severe withdrawal, overdose, seizures and psychiatric crises. A complete history helps a service decide whether it can safely accept the referral or whether another level of care is needed first.

Psychiatric University Hospital Zurich describes outpatient, day and inpatient care for addiction disorders and dual diagnoses, including withdrawal treatment. Its published target population is adults aged eighteen to sixty-five, preferably residents of the canton of Zurich. Confirm the applicable referral criteria and suitable program directly; this description is not an assurance of access for every Swiss resident. [4]

Geneva University Hospitals describes outpatient and hospital addiction care, with psychiatric needs considered within the service. Its hospital transition unit is in Chêne-Bourg and has a planned, voluntary admission route. Ask which team should assess the person’s substance history and what medical withdrawal care it can provide. A named hospital system does not establish that every unit offers the same treatment. [5] [7]

These clinical routes can inform a comparison even when a person prefers a private residential setting later. They help establish the level of care and the services that should be present. Verify language, referral eligibility, timing and funding individually instead of inferring them from residence in Switzerland or from a hospital’s public status.

For opioid use disorder, the CDC recommends medication treatment and advises against detoxification alone because of the risk of returning to use and overdose. A Swiss provider should explain how the appropriate ongoing medical pathway is provided or arranged locally. The purpose of assessment is to establish that plan, not simply to select a short period without drugs. [2]

Ask which clinician remains responsible after the medical phase and how that responsibility transfers if residential care occurs in Spain. The receiving service needs to accept the medical requirements before travel. An essential prescription should not depend on a conversation that everyone assumes another team has already had.

Overdose-prevention education and an appropriate naloxone discussion also belong with the responsible medical team. Where pain medication is involved, include the original pain condition and existing specialist care in the assessment. A comprehensive plan should make room for both the medical indication and any harmful use, rather than allow one to obscure the other. [2]

Physical dependence on a benzodiazepine is different from a substance use disorder and can develop during prescribed treatment. The joint clinical guideline emphasizes that distinction. Ask the service whether it is recommending prescribing review, treatment for addiction, care for the original condition or a combination. A broad drug-detox package should not impose a diagnosis before the assessment. [1]

The FDA warns that abrupt stopping or rapid reduction can cause serious benzodiazepine withdrawal, including seizures. Alcohol and opioids can increase risks when used with these medicines. Medication should not be independently changed to simplify a journey or to satisfy the advertised length of a program. The responsible clinician should determine the appropriate plan and care setting. [8]

Some clinician-led medication changes may require prolonged follow-up. Ask how the proposed service would coordinate a process that extends beyond an admission, and whether the Swiss prescriber is willing and able to accept the plan. A discharge recommendation is not the same as an agreed appointment or an accepted prescribing responsibility. [1]

ASAM and AAAP guidance recognizes medical and psychiatric complications in stimulant intoxication and withdrawal. The proposed provider should explain its assessment, acute-care limits and treatment after stabilization. The ability to manage another type of withdrawal is not sufficient evidence of the necessary stimulant-related expertise. [9]

If several substances are involved, ask who coordinates the whole medical picture. Include medicines from different prescribers, nonprescribed drugs and alcohol, even when their use seems secondary. The person should receive a coherent explanation rather than separate instructions that leave them to resolve possible conflicts alone.

Also ask how the service distinguishes current substance-related symptoms from mental health concerns that need continued assessment. A program may provide addiction and psychiatric care while still requiring acute hospital treatment for some presentations. The important point is to know the actual limits and the plan if the person’s condition changes. [3]

Before arranging a Mallorca stay, the Swiss medical service and COGNIFUL should agree on the relevant history, current treatment and unresolved needs. Ask what information the residence requires to decide suitability and who will provide it. Discharge from one service does not automatically mean that another has accepted the person or can support every ongoing medical requirement.

Discuss the language of records and consultations. The person should understand the plan, and the receiving clinician should be able to use the medical documentation. If translation or clarification is needed, arrange it before the handover rather than rely on a family member to interpret complex instructions during travel.

Confirm medication and travel requirements through the appropriate authorities and clinicians. Cross-border availability or prescribing should not be assumed. The return journey should include a Swiss follow-up appointment and an identified professional for any continuing treatment. A residential program can help organize a transition, but it cannot substitute for the receiving service’s acceptance.

COGNIFUL assesses suitability for its Mallorca program, including substance use, withdrawal risk and current medical and psychiatric needs. Its published prescription-medication information and clinical standards place medical needs within that review. When detox or another medical setting is necessary first, that should be arranged as a separate stage. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. [10] [3]

After stabilization, suitable residential work may address the person’s pattern of use, coping, relationships and return to everyday responsibilities. Ask what specific goals would justify the stay and which professionals would work on them. The plan should connect with the medical care already received instead of treating discharge from detox as a new assessment-free starting point.

At any time, the residence accommodates a maximum of four clients, each in a private suite. Clinical and bodywork sessions are individual. The residence, chef, personal manager, other holistic sessions, activities and excursions are shared. These features clarify the experience of living there; they do not establish a particular staffing ratio, hospital equipment or guaranteed clinical outcome. [6]

COGNIFUL Premier and Premier Plus both include assessment, a personal plan and continuing-care planning. Every session and activity is individual, family and transition work, and three months of aftercare are included in Plus. Follow-up under the base program is agreed individually. Typical residential stays span four to twelve weeks with individual review. [6] View program fees

Those residential fees and lengths should not be described as a detox quotation or a withdrawal schedule. A written proposal should set out duration, inclusions, total costs and any separately arranged medical services. COGNIFUL generally operates through self-payment without direct insurer billing or guaranteed reimbursement. Verify any potential coverage directly rather than assume a Swiss policy funds care abroad. [6]

Ask how continuing care would connect with the Swiss team, including consent, records, appointments and prescribing responsibilities. The support included in the actual agreement should be explicit. Do not infer unrestricted cross-border clinical access from the word aftercare; essential local care needs an accepted local arrangement. [11] [3]

• Which substance-related need determines the recommended medical setting?
• Is the accepting Swiss service appropriate for the person’s age, referral and history?
• Who will continue opioid or other necessary medication treatment?
• What conditions must be met before transfer to a Mallorca residence?
• How are costs and bookings handled if clinical needs change?

Ask for the whole sequence in understandable language, including the next appointment after each stage. A good comparison may lead to treatment within Switzerland, or to Swiss medical care followed by a suitable residential stay. The pathway should remain responsive to assessment instead of requiring recovery to fit a predetermined itinerary.

Are Swiss hospital services relevant to a private detox search?

Yes. They provide useful clinical routes to assess withdrawal and continuing treatment needs. Exact access, referral and program suitability must be confirmed directly. [4] [5]

Does opioid detox complete treatment?

For opioid use disorder, detoxification alone is not recommended. Medication treatment and ongoing clinical care should be offered or arranged. [2]

Can dependence on a prescribed sedative occur without addiction?

Yes. The benzodiazepine guideline distinguishes physical dependence from substance use disorder. The appropriate diagnosis and treatment require assessment. [1]

Is COGNIFUL based in Switzerland?

COGNIFUL is in Mallorca, Spain. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. Suitability for care after necessary stabilization is reviewed individually. [6] [3]

COGNIFUL admissions can consider the Swiss treatment plan and explain whether a Mallorca stay may fit. If there is suspected overdose, breathing difficulty, severe confusion, a seizure or immediate danger, seek urgent local medical help before arranging an international journey. [6] [8]

1. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
2. Opioid use disorder: treating — Centers for Disease Control and Prevention.
3. Clinical scope, suitability and care coordination — COGNIFUL.
4. Addiction disorders and dual diagnoses — Psychiatric University Hospital Zurich.
5. Addictology service care options — Geneva University Hospitals.
6. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
7. Hospital transition unit in addictology — Geneva University Hospitals.
8. Benzodiazepine safety communication — US Food and Drug Administration.
9. Clinical Practice Guideline on the Management of Stimulant Use Disorder — American Society of Addiction Medicine and American Academy of Addiction Psychiatry.
10. Prescription medication concerns and residential treatment — COGNIFUL.
11. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.